Continuing Adjunctive Antidepressant Treatment For Up To One Year Following Remission Of Acute Depressive Episode In Patients With Bipolar I Disorder May Not Prevent Relapse, Trial Finds

MedPage Today (8/2, DePeau-Wilson) reports “continuing adjunctive antidepressant treatment for up to a year following remission of an acute depressive episode in patients with bipolar I disorder showed no significant benefit for preventing relapse, a randomized trial showed.” At 52 weeks, about “31% of patients treated with maintenance escitalopram (Lexapro) or bupropion XL (Wellbutrin XL) for that duration of time experienced a subsequent mood episode, as compared with 46% of those who switched to placebo at 8 weeks.” The findings were published online in the New England Journal of Medicine.

Related Links:

MedPage Today (requires login and subscription)

Posted in In The News.